Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 3
Submit an article Journal homepage
4,750
Views
73
CrossRef citations to date
0
Altmetric
Original Research

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

Xinru WeiKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Yunxin LaiKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaORCID Iconhttp://orcid.org/0000-0003-3673-149X
ORCID Icon,
Jin LiState Key Laboratory of Respiratory Disease, The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, China
,
Le QinKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Youdi XuKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Ruocong ZhaoKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Baiheng LiKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Simiao LinKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Suna WangKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Qiting WuKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Qiubin LiangGuangdong Zhaotai In Vivo Biomedicine Co. Ltd, Guangzhou, China
,
Muyun PengDepartment of Thoracic Oncology, The Second Xiangya Hospital of Central South University, Changcha, China
,
Fenglei YuDepartment of Thoracic Oncology, The Second Xiangya Hospital of Central South University, Changcha, China
,
Yangqiu LiInstitute of Hematology, Medical College, Jinan University, Guangzhou, China
,
Xuchao ZhangGuangdong Lung Cancer Institute, Medical Research Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
,
Yilong WuGuangdong Lung Cancer Institute, Medical Research Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
,
Pentao LiuWellcome Trust Sanger Institute, Hinxton, Cambridge, UKORCID Iconhttp://orcid.org/0000-0001-5774-9678
ORCID Icon,
Duanqing PeiKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
,
Yao YaoKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCorrespondence[email protected] [email protected]
&
Peng LiKey Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCorrespondence[email protected] [email protected]
 show all
Article: e1284722 | Received 21 Dec 2016, Accepted 16 Jan 2017, Published online: 15 Mar 2017

Citations (73)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

John Maher. (2023) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives. OncoTargets and Therapy 16, pages 515-532.
Read now
Maya Glover, Stephanie Avraamides & John Maher. (2021) How Can We Engineer CAR T Cells to Overcome Resistance?. Biologics: Targets and Therapy 15, pages 175-198.
Read now
Fiamma Berner, Rebekka Niederer, Jolien J. Luimstra, Oltin Tiberiu Pop, Ann-Kristin Jochum, Mette-Triin Purde, Omar Hasan Ali, David Bomze, Jens Bauer, Lena Katharina Freudenmann, Ana Marcu, Eva-Maria Wolfschmitt, Sebastian Haen, Thorben Gross, Marissa Lisa Dubbelaar, Marie-Therese Abdou, Petra Baumgaertner, Christina Appenzeller, Caroline Cicin-Sain, Tobias Lenz, Daniel E. Speiser, Burkhard Ludewig, Christoph Driessen, Markus Jörger, Martin Früh, Wolfram Jochum, Antonio Cozzio, Hans-Georg Rammensee, Juliane Walz, Jacques Neefjes & Lukas Flatz. (2021) Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. OncoImmunology 10:1.
Read now
Linqin Wang, Elaine Tan Su Yin, Houli Zhao, Fang Ni, Yongxian Hu & He Huang. (2020) CAR-T cells: the Chinese experience. Expert Opinion on Biological Therapy 20:11, pages 1293-1308.
Read now
Shao Weimin, Asimujiang Abula, Ding Qianghong & Wang Wenguang. (2020) Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biology & Therapy 21:6, pages 570-580.
Read now
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar & Michael T. Lotze. (2019) Making cold malignant pleural effusions hot: driving novel immunotherapies. OncoImmunology 8:4.
Read now
Ruocong Zhao, Lin Cheng, Zhiwu Jiang, Xinru Wei, Baiheng Li, Qiting Wu, Suna Wang, Simiao Lin, Youguo Long, Xuchao Zhang, Yilong Wu, Xin Du, Duanqing Pei, Pentao Liu, Yangqiu Li, Shuzhong Cui, Yao Yao & Peng Li. (2019) DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. OncoImmunology 8:1.
Read now
Shouheng Lin, Guohua Huang, Lin Cheng, Zhen Li, Yiren Xiao, Qiuhua Deng, Yuchuan Jiang, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Huihui Yao, Su Cao, Yang Li, Pentao Liu, Wei Wei, Duanqing Pei, Yao Yao, Zhesheng Wen, Xuchao Zhang, Yilong Wu, Zhenfeng Zhang, Shuzhong Cui, Xiaofang Sun, Xueming Qian & Peng Li. (2018) Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. mAbs 10:8, pages 1301-1311.
Read now

Articles from other publishers (65)

Hong Ma, Jeeban Das, Conor Prendergast, Dorine De Jong, Brian Braumuller, Jacienta Paily, Sophia Huang, Connie Liou, Anna Giarratana, Mahdie Hosseini, Randy Yeh & Kathleen Capaccione. (2023) Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer. Current Issues in Molecular Biology 45:11, pages 9019-9038.
Crossref
Rubén Arroyo-Olarte, Aranza Mejía-Muñoz & Sonia León-Cabrera. (2023) Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer. Molecular Diagnosis & Therapy.
Crossref
Aying Wang, Tangfeng Lv & Yong Song. (2023) Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. Cellular Immunology 391-392, pages 104760.
Crossref
Xiaotong Lin, Yao Sun, Xin Dong, Zishen Liu, Ryohichi Sugimura & Guozhu Xie. (2023) IPSC-derived CAR-NK cells for cancer immunotherapy. Biomedicine & Pharmacotherapy 165, pages 115123.
Crossref
Yasuyuki Matsumoto & Tongzhong Ju. (2023) Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. Cancers 15:14, pages 3536.
Crossref
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem, Ravi Chauhan, Manisha Dagar, Sameer Mirza, Puneet Bagga, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Mohammad Haris, Shahab Uddin, Mayank Singh & Ajaz A. Bhat. (2023) Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of Translational Medicine 21:1.
Crossref
Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee & Manash K. Paul. (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer 22:1.
Crossref
Sara Pagotto, Pasquale Simeone, Davide Brocco, Giulia Catitti, Domenico De Bellis, Simone Vespa, Natalia Di Pietro, Lisa Marinelli, Antonio Di Stefano, Serena Veschi, Laura De Lellis, Fabio Verginelli, Francesco Kaitsas, Manuela Iezzi, Assunta Pandolfi, Rosa Visone, Nicola Tinari, Ignazio Caruana, Mauro Di Ianni, Alessandro Cama, Paola Lanuti & Rosalba Florio. (2023) CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy. Cancers 15:4, pages 1052.
Crossref
Karama Makni Maalej, Maysaloun Merhi, Varghese P. Inchakalody, Sarra Mestiri, Majid Alam, Cristina Maccalli, Honar Cherif, Shahab Uddin, Martin Steinhoff, Francesco M. Marincola & Said Dermime. (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Molecular Cancer 22:1.
Crossref
Weiqiu Jin, Mengwei Zhang, Changzi Dong, Lei Huang & Qingquan Luo. (2022) The multifaceted role of MUC1 in tumor therapy resistance. Clinical and Experimental Medicine 23:5, pages 1441-1474.
Crossref
Faroogh Marofi, Harun Achmad, Dmitry Bokov, Walid Kamal Abdelbasset, Zeid Alsadoon, Supat Chupradit, Wanich Suksatan, Siavash Shariatzadeh, Zahra Hasanpoor, Mahboubeh Yazdanifar, Navid Shomali & Farhad Motavalli Khiavi. (2022) Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Research & Therapy 13:1.
Crossref
Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee & Raja Ganesan. (2022) Advances in the Lung Cancer Immunotherapy Approaches. Vaccines 10:11, pages 1963.
Crossref
Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye, Zhixiong Liu & Quan Cheng. (2022) Tumor buster - where will the CAR-T cell therapy ‘missile’ go?. Molecular Cancer 21:1.
Crossref
Jing Tu, Min Tang, Guoqing Li, Liang Chen, Yubo Wang & Yong Huang. (2022) Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and its Role in Evaluation of Prognosis. Journal of Oncology 2022, pages 1-16.
Crossref
Lianxiang Luo, Manshan Li, Jiating Su, Xinyue Yao & Hui Luo. (2021) FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma. Clinical and Experimental Medicine 22:3, pages 371-384.
Crossref
Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei & Yunchao Huang. (2022) Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Frontiers in Immunology 13.
Crossref
Jiangang Sun, Xiaojing Li, Peng Chen & Yongshun Gao. (2022) From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Journal of Inflammation Research Volume 15, pages 4061-4085.
Crossref
Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Saqer S. Alotaibi, Mohammad M. Al-Sanea & Hisham Althobaiti. (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Zhiwu Jiang, Lin Cheng, Zhiping Wu, Linfu Zhou, Haitao Wang, Qilan Hong, Qiting Wu, Youguo Long, Yunlin Huang, Gaoqi Xu, Yao Yao, Zhaoyang Tang, Zhenfeng Zhang, Lili Yang, Wei Luo, Jie Yang, Likun Gong, Pentao Liu, Xinwen Chen, Shuzhong Cui, Qi Zhang, Yinxiong Li & Peng Li. (2022) Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO reports 23:6.
Crossref
Prameela Kandra, Rajender Nandigama, Bastian Eul, Magdalena Huber, Sebastian Kobold, Werner Seeger, Friedrich Grimminger & Rajkumar Savai. (2022) Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Frontiers in Immunology 13.
Crossref
Luisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, Maite Martínez-Aguillo, Sergio Piñeiro-Hermida, Pablo Ramos, Juan José Lasarte, Ruth Vera, Grazyna Kochan & David Escors. (2022) CAR-T Cells for the Treatment of Lung Cancer. Life 12:4, pages 561.
Crossref
Long Chen, Fukun Chen, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Yujie Lei & Yunchao Huang. (2022) CAR‐T cell therapy for lung cancer: Potential and perspective . Thoracic Cancer 13:7, pages 889-899.
Crossref
Kun-Yu Teng, Anthony G. Mansour, Zheng Zhu, Zhiyao Li, Lei Tian, Shoubao Ma, Bo Xu, Ting Lu, Hanyu Chen, David Hou, Jianying Zhang, Saul J. Priceman, Michael A. Caligiuri & Jianhua Yu. (2022) Off-the-Shelf Prostate Stem Cell Antigen–Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. Gastroenterology 162:4, pages 1319-1333.
Crossref
Ler Yie Chan, Sylvia Annabel Dass, Gee Jun Tye, Siti A. M. Imran, Wan Safwani Wan Kamarul Zaman & Fazlina Nordin. (2022) CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines 10:4, pages 804.
Crossref
Anh Nguyen, Gary Johanning & Yihui Shi. (2022) Emerging Novel Combined CAR-T Cell Therapies. Cancers 14:6, pages 1403.
Crossref
Tongqing Xue, Xiang Zhao, Kun Zhao, Yan Lu, Juan Yao & Xianguo Ji. (2022) Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Current Problems in Cancer 46:1, pages 100791.
Crossref
Nora Berois, Alvaro Pittini & Eduardo Osinaga. (2022) Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers 14:3, pages 645.
Crossref
Ayda Baghery Saghchy Khorasani, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Seyed H. Ghaffari & Davood Bashash. (2021) CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. International Immunopharmacology 101, pages 108260.
Crossref
Bu-Fan Xiao, Jing-Tao Zhang, Yu-Ge Zhu, Xin-Run Cui, Zhe-Ming Lu, Ben-Tong Yu & Nan Wu. (2021) Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology 12.
Crossref
Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto & Koji Tamada. (2021) Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunology, Immunotherapy 70:9, pages 2503-2515.
Crossref
Lele Miao, Zhengchao Zhang, Zhijian Ren, Futian Tang & Yumin Li. (2021) Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Frontiers in Immunology 12.
Crossref
Zhiwu Jiang, Rui Liao, Jiang Lv, Shanglin Li, Diwei Zheng, Le Qin, Di Wu, Suimin Chen, Youguo Long, Qiting Wu, Suna Wang, Simiao Lin, Xiaohan Huang, Zhaoyang Tang, Pengcheng Shi, Hongsheng Zhou, Qifa Liu, Ruocong Zhao, Yangqiu Li, Yang Jie, Wei Wei, Peilong Lai, Xin Du, Shuzhong Cui, Robert Weinkove, Pentao Liu, Duanqing Pei, Yao Yao & Peng Li. (2020) IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia 35:5, pages 1380-1391.
Crossref
Shouheng Lin, Lin Cheng, Wei Ye, Shanglin Li, Diwei Zheng, Le Qin, Qiting Wu, Youguo Long, Simiao Lin, Suna Wang, Guohua Huang, Peng Li, Yao Yao & Xiaofang Sun. (2021) Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies. Frontiers in Immunology 12.
Crossref
Liyuan Jin, Lei Cao, Yingjie Zhu, Jiani Cao, Xiaoyan Li, Jianxia Zhou, Bing Liu & Tongbiao Zhao. (2021) Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6. Science Bulletin 66:8, pages 803-812.
Crossref
Adam J. Schoenfeld & Roisin E. O'Cearbhaill. (2021) How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. The Cancer Journal 27:2, pages 134-142.
Crossref
Jingjing Qu, Quanhui Mei, Lijun Chen & Jianying Zhou. (2020) Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunology, Immunotherapy 70:3, pages 619-631.
Crossref
Faroogh Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi & Farhad Motavalli Khiavi. (2021) CAR T cells in solid tumors: challenges and opportunities. Stem Cell Research & Therapy 12:1.
Crossref
嬿羽 遆. (2021) Application of Chimeric Antigen Receptor-T Cell (CAR-T) in Non-Small Cell Lung Cancer. Advances in Clinical Medicine 11:10, pages 4373-4377.
Crossref
Lei Yu, Zhichao Li, Hongbin Mei, Wujiao Li, Dong Chen, Lisa Liu, Zhongfu Zhang, Yangyang Sun, Fei Song, Wei Chen & Weiren Huang. (2021) Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro . Clinical & Translational Immunology 10:2.
Crossref
Xuefeng Tang, Zhao Wang, Feng Wei, Wei Mu & Xiaojun Han. (2020) Recent Progress of Lung Cancer Diagnosis Using Nanomaterials. Crystals 11:1, pages 24.
Crossref
Di Wu, Jiang Lv, Ruocong Zhao, Zhiping Wu, Diwei Zheng, Jingxuan Shi, Simiao Lin, Suna Wang, Qiting Wu, Youguo Long, Peng Li & Yao Yao. (2020) PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research 8:1.
Crossref
Le Qin, Ruocong Zhao, Dongmei Chen, Xinru Wei, Qiting Wu, Youguo Long, Zhiwu Jiang, Yangqiu Li, Haipeng Wu, Xuchao Zhang, Yilong Wu, Shuzhong Cui, Wei Wei, Huihui Yao, Zixia Liu, Su Cao, Yao Yao, Zhenfeng Zhang & Peng Li. (2020) Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomarker Research 8:1.
Crossref
Niels Schaft. (2020) The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview. Cancers 12:9, pages 2567.
Crossref
Hongjian Li, Cheng Huang, Zongliang Zhang, Yunyu Feng, Zeng Wang, Xin Tang, Kunhong Zhong, Yating Hu, Gang Guo, Liangxue Zhou, Wenhao Guo, Jianguo Xu, Hui Yang & Aiping Tong. (2020) MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody. Frontiers in Oncology 10.
Crossref
Hongyu Xu, Hui Gao, Hua Li, Dong Li, Weiwei Yuan, Ling Zhang, Peng Cheng, Xiaomei Su, Zhihui Li, Guangjie Wang & Tao Zhang. (2020) Downregulated Mucin 1 alleviates paclitaxel resistance in non‑small cell lung cancer cells. Molecular Medicine Reports.
Crossref
Ziming Hu, Xiaohu Zheng, Defeng Jiao, Yonggang Zhou, Rui Sun, Baolong Wang, Zhigang Tian & Haiming Wei. (2020) LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer. Molecular Therapy - Oncolytics 17, pages 361-370.
Crossref
Camille Jacqueline & Olivera J. Finn. (2020) Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. Seminars in Immunology 47, pages 101394.
Crossref
Zahra Rashidijahanabad & Xuefei Huang. (2020) Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy. Seminars in Immunology 47, pages 101390.
Crossref
Le Van Manh Hung, Hieu Trong Ngo & Phuc Van Pham. 2020. Cancer Biology and Advances in Treatment. Cancer Biology and Advances in Treatment 113 130 .
Zi Mei, Kai Zhang, Alfred King‐Yin Lam, Junwen Huang, Feng Qiu, Bin Qiao & Yi Zhang. (2019) MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma. Cancer Medicine 9:2, pages 640-652.
Crossref
Jiang Lv, Ruocong Zhao, Di Wu, Diwei Zheng, Zhiping Wu, Jingxuan Shi, Xinru Wei, Qiting Wu, Youguo Long, Simiao Lin, Suna Wang, Zhi Wang, Yang Li, Yantao Chen, Qing He, Suimin Chen, Huihui Yao, Zixia Liu, Zhaoyang Tang, Yao Yao, Duanqing Pei, Pentao Liu, Xuchao Zhang, Zhenfeng Zhang, Shuzhong Cui, Ren Chen & Peng Li. (2019) Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. Journal of Hematology & Oncology 12:1.
Crossref
Maria C. Ramello, Ismahène Benzaïd, Brent M. Kuenzi, Maritza Lienlaf-MorenoWendy M. Kandell, Daniel N. SantiagoMibel Pabón-Saldaña, Lancia DarvilleBin Fang, Uwe Rix, Sean YoderAnders Berglund, John M. Koomen, Eric B. Haura & Daniel Abate-Daga. (2019) An immunoproteomic approach to characterize the CAR interactome and signalosome. Science Signaling 12:568.
Crossref
Ruidi Teng, Jingjing Zhao, Yiding Zhao, Junshuang Gao, Haibo Li, Shixin Zhou, Yuan Wang, Qiang Sun, Zhongqing Lin, Weifeng Yang, Ming Yin, Jinhua Wen & Hongkui Deng. (2019) Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. Journal of Immunotherapy 42:2, pages 33-42.
Crossref
Sunyoung S. Lee & Grace K. Dy. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer 45 75 .
Louqian Zhang, Weifei Fan, Li Xu, Qixing Mao, Yan Chen, Yuan Mao, Lin Xu & Jun Wang. (2018) Rab27b Is a Potential Indicator for Lymph Node Metastasis and Unfavorable Prognosis in Lung Adenocarcinoma. Disease Markers 2018, pages 1-8.
Crossref
Michelle H. Townsend, Gajendra Shrestha, Richard A. Robison & Kim L. O’Neill. (2018) The expansion of targetable biomarkers for CAR T cell therapy. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Yanyu Pang, Xiaoyang Hou, Chunsheng Yang, Yanqun Liu & Guan Jiang. (2018) Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Molecular Cancer 17:1.
Crossref
Kavitha Gowrishankar, Lucy Birtwistle & Kenneth Micklethwaite. (2018) Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mammalian Genome 29:11-12, pages 739-756.
Crossref
Matthew J. Buettner, Sagar R. Shah, Christopher T. Saeui, Ryan Ariss & Kevin J. Yarema. (2018) Improving Immunotherapy Through Glycodesign. Frontiers in Immunology 9.
Crossref
Mei Guo, Chengzhong You & Jun Dou. (2018) Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Biomedicine & Pharmacotherapy 107, pages 1318-1325.
Crossref
Dapeng Zhou, Lan Xu, Wei Huang & Torsten Tonn. (2018) Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy. Molecules 23:6, pages 1326.
Crossref
Nan Chen, Xiaoyu Li, Navin K Chintala, Zachary E Tano & Prasad S Adusumilli. (2018) Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Current Opinion in Immunology 51, pages 103-110.
Crossref
Shivani Srivastava & Stanley R. Riddell. (2018) Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. The Journal of Immunology 200:2, pages 459-468.
Crossref
Stefan Kiesgen, Leonardo Chicaybam, Navin K. Chintala & Prasad S. Adusumilli. (2018) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. Journal of Thoracic Oncology 13:1, pages 16-26.
Crossref
Brigitte M. Pützer, Manish Solanki & Ottmar Herchenröder. (2017) Advances in cancer stem cell targeting: How to strike the evil at its root. Advanced Drug Delivery Reviews 120, pages 89-107.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.